The American Lung Association (ALA) is launching a trial that will determine whether omalizumab — which is already approved by the U.S. Food and Drug Administration (FDA) for asthma and allergic diseases — can help reduce flare-ups in patients with COPD who are sensitized and exposed to common allergens in their homes.
According to a press release, the COPD-OMA trial will be conducted through the association’s Airways Clinical Research Centers (ACRC) and is funded by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID).
“COPD remains a leading cause of death and disability in the United States, and many people with COPD continue to experience dangerous and disruptive flare-ups despite current treatments,” said Harold Wimmer, president and CEO of the American Lung Association. “Through this important research, we aim to determine whether an existing, proven medication could offer new hope to people living with COPD and allergies. This study has the potential to significantly improve quality of life for millions.”
Each participant will be in the study for about 16 months, including one to three months of screening, 12 months of clinical treatment and a follow-up call one month after the last clinical visit. The researchers are looking for participants aged 40 years and older with COPD who also have known allergens in their home, such as pet dander, dust mites or cockroaches.
Primary completion of the study is estimated to be in early 2031.
